{"id":47565,"date":"2022-08-23T12:01:50","date_gmt":"2022-08-23T10:01:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/"},"modified":"2022-08-23T12:01:50","modified_gmt":"2022-08-23T10:01:50","slug":"new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/","title":{"rendered":"New Survey from Vizient Provides Hospital Insights into Biosimilar Adoption and What is Preventing Greater Utilization"},"content":{"rendered":"<div>\n<p>IRVING, Texas&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vizientinc.com%2F&amp;esheet=52822878&amp;newsitemid=20220823005279&amp;lan=en-US&amp;anchor=Vizient%2C+Inc.&amp;index=1&amp;md5=1cc88f26e2fad03531f1afb46de12557\" rel=\"nofollow noopener\" shape=\"rect\">Vizient, Inc.<\/a> announced today the results of its <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vizientinc.com%2F-%2Fmedia%2Fdocuments%2Fsitecorepublishingdocuments%2Fpublic%2Fbiosimilar_survey_detailed_results.pdf&amp;esheet=52822878&amp;newsitemid=20220823005279&amp;lan=en-US&amp;anchor=2022+biosimilar+survey&amp;index=2&amp;md5=7347f2ad20d23dc2b01ad03b99971a33\" rel=\"nofollow noopener\" shape=\"rect\">2022 biosimilar survey<\/a>, which demonstrate significant biosimilar adoption to hospital formularies, but lagging utilization in patient care.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220823005279\/en\/637378\/5\/Vizient_Logo_V2.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220823005279\/en\/637378\/21\/Vizient_Logo_V2.jpg\"><\/a><\/p>\n<p>\nThe survey of hospital leaders and pharmacy professionals from Vizient member hospitals across the country found that biosimilars are gaining inclusion in hospital formularies, something long seen as a necessity for greater adoption. The majority of respondents (80%) said they have instituted a system-wide review process for biosimilar adoption to their formularies, while the drivers of adoption were shown to be different:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n30% of respondents said they adopted biosimilars under provider or payer demand.\n<\/li>\n<li>\n25%, when approved by the organization\u2019s pharmaceutical and therapeutics committee.\n<\/li>\n<li>\n22%, once they are FDA-approved, and 20% reported no procedure at all.\n<\/li>\n<\/ul>\n<p>\nAccording to respondents, the longer a biosimilar has been available, the more likely the product is to be added to an organization\u2019s formulary, but the length of time did not necessarily translate into higher utilization. For example, 88% of respondents said they have adopted a biosimilar for infliximab (Remicade<sup>\u00ae<\/sup>), used in the treatment of rheumatoid arthritis and inflammatory bowel conditions, and 85% said they are utilizing it to some degree. However, Vizient and national purchase information reveals that the originator product retains a larger market share relative to the competing infliximab biosimilar.\n<\/p>\n<p>\n\u201cVizient has long urged the adoption of biosimilars to our member healthcare organizations to compete with their branded biologic counterparts as they are just as safe and effective,\u201d said <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnewsroom.vizientinc.com%2Fsteven-lucio-pharmd-bcps.htm&amp;esheet=52822878&amp;newsitemid=20220823005279&amp;lan=en-US&amp;anchor=Steven+Lucio&amp;index=3&amp;md5=2ebef0d554de3ac50d609e9fc8e52ae6\" rel=\"nofollow noopener\" shape=\"rect\">Steven Lucio<\/a>, senior principal, pharmacy solutions, for Vizient. \u201cThe introduction of additional biosimilars signals a real savings opportunity for healthcare organizations and their patients.\u201d\n<\/p>\n<p>\nRespondents reported that the primary circumstances that drive biosimilar utilization were new treatment starts (65%) and payer coverage for individual patients (59%). However, nearly half of respondents (48%) said they eventually convert patients over time, such as in the start of the next treatment cycle.\n<\/p>\n<p>\n<b>Reimbursement remains the biggest barrier<\/b>\n<\/p>\n<p>\nWhile biosimilars have largely gained clinical acceptability, the alignment between provider selection and payer coverage remains a challenge. Respondents reported payer demands for specific products as the top barrier to automatic therapeutic substitution, followed by provider acceptance, and management of the prior authorization process. In relation to preparation for Humira<sup>\u00ae<\/sup> (adalimumab) biosimilars, which will enter the market in 2023, respondents identified payer placement, acquisition price, and interchangeability status as the top three attributes that will govern product selection and inclusion in a hospital\u2019s formulary.\n<\/p>\n<p>\nThe survey of pharmacy professionals and executives was conducted between March 30 and April 28, 2022 and collected 124 responses. Highlights from the survey report can be accessed online <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vizientinc.com%2F-%2Fmedia%2Fdocuments%2Fsitecorepublishingdocuments%2Fpublic%2Fbiosimilar_survey_summary_results.pdf&amp;esheet=52822878&amp;newsitemid=20220823005279&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=02c35e8f08ee90ac4c3263847d99cea1\" rel=\"nofollow noopener\" shape=\"rect\">here<\/a>.\n<\/p>\n<p>\n<b>About Vizient, Inc.<\/b>\n<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnewsroom.vizientinc.com%2F&amp;esheet=52822878&amp;newsitemid=20220823005279&amp;lan=en-US&amp;anchor=Vizient%2C+Inc&amp;index=5&amp;md5=0395612633fee84fe2a33f7d14f3aa54\" rel=\"nofollow noopener\" shape=\"rect\">Vizient, Inc<\/a>., the nation\u2019s largest health care performance improvement company, serves more than 50% of the nation\u2019s acute care providers, which includes 97% of the nation\u2019s academic medical centers, and more than 20% of ambulatory care providers. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $130 billion in annual purchasing volume. Vizient\u2019s solutions and services improve the delivery of high-value care by aligning cost, quality and market performance. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vizientinc.com&amp;esheet=52822878&amp;newsitemid=20220823005279&amp;lan=en-US&amp;anchor=www.vizientinc.com&amp;index=6&amp;md5=df74bed32ee3b50d738486fc6aaa2fd8\" rel=\"nofollow noopener\" shape=\"rect\">www.vizientinc.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nDonna Ledbetter<br \/>\n<br \/>(972) 830-6321<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;t&#x6f;&#x3a;&#x64;&#111;nn&#x61;&#x2e;&#108;&#101;d&#x62;&#x65;&#x74;&#116;er&#x40;&#x76;&#105;&#122;i&#x65;&#x6e;&#x74;&#105;nc&#x2e;&#x63;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x64;o&#x6e;&#110;a&#x2e;&#108;&#x65;&#100;b&#x65;&#116;&#x74;&#101;r&#x40;&#118;&#x69;&#x7a;i&#x65;&#110;t&#x69;&#110;&#x63;&#46;c&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>IRVING, Texas&#8211;(BUSINESS WIRE)&#8211;Vizient, Inc. announced today the results of its 2022 biosimilar survey, which demonstrate significant biosimilar adoption to hospital formularies, but lagging utilization in patient care. The survey of hospital leaders and pharmacy professionals from Vizient member hospitals across the country found that biosimilars are gaining inclusion in hospital formularies, something long seen as &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47565","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Survey from Vizient Provides Hospital Insights into Biosimilar Adoption and What is Preventing Greater Utilization - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Survey from Vizient Provides Hospital Insights into Biosimilar Adoption and What is Preventing Greater Utilization - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"IRVING, Texas&#8211;(BUSINESS WIRE)&#8211;Vizient, Inc. announced today the results of its 2022 biosimilar survey, which demonstrate significant biosimilar adoption to hospital formularies, but lagging utilization in patient care. The survey of hospital leaders and pharmacy professionals from Vizient member hospitals across the country found that biosimilars are gaining inclusion in hospital formularies, something long seen as ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-23T10:01:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220823005279\/en\/637378\/21\/Vizient_Logo_V2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"New Survey from Vizient Provides Hospital Insights into Biosimilar Adoption and What is Preventing Greater Utilization\",\"datePublished\":\"2022-08-23T10:01:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\\\/\"},\"wordCount\":542,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220823005279\\\/en\\\/637378\\\/21\\\/Vizient_Logo_V2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\\\/\",\"name\":\"New Survey from Vizient Provides Hospital Insights into Biosimilar Adoption and What is Preventing Greater Utilization - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220823005279\\\/en\\\/637378\\\/21\\\/Vizient_Logo_V2.jpg\",\"datePublished\":\"2022-08-23T10:01:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220823005279\\\/en\\\/637378\\\/21\\\/Vizient_Logo_V2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220823005279\\\/en\\\/637378\\\/21\\\/Vizient_Logo_V2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Survey from Vizient Provides Hospital Insights into Biosimilar Adoption and What is Preventing Greater Utilization\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Survey from Vizient Provides Hospital Insights into Biosimilar Adoption and What is Preventing Greater Utilization - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/","og_locale":"en_US","og_type":"article","og_title":"New Survey from Vizient Provides Hospital Insights into Biosimilar Adoption and What is Preventing Greater Utilization - Pharma Trend","og_description":"IRVING, Texas&#8211;(BUSINESS WIRE)&#8211;Vizient, Inc. announced today the results of its 2022 biosimilar survey, which demonstrate significant biosimilar adoption to hospital formularies, but lagging utilization in patient care. The survey of hospital leaders and pharmacy professionals from Vizient member hospitals across the country found that biosimilars are gaining inclusion in hospital formularies, something long seen as ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-23T10:01:50+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220823005279\/en\/637378\/21\/Vizient_Logo_V2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"New Survey from Vizient Provides Hospital Insights into Biosimilar Adoption and What is Preventing Greater Utilization","datePublished":"2022-08-23T10:01:50+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/"},"wordCount":542,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220823005279\/en\/637378\/21\/Vizient_Logo_V2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/","url":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/","name":"New Survey from Vizient Provides Hospital Insights into Biosimilar Adoption and What is Preventing Greater Utilization - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220823005279\/en\/637378\/21\/Vizient_Logo_V2.jpg","datePublished":"2022-08-23T10:01:50+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220823005279\/en\/637378\/21\/Vizient_Logo_V2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220823005279\/en\/637378\/21\/Vizient_Logo_V2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/new-survey-from-vizient-provides-hospital-insights-into-biosimilar-adoption-and-what-is-preventing-greater-utilization\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"New Survey from Vizient Provides Hospital Insights into Biosimilar Adoption and What is Preventing Greater Utilization"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47565"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47565\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}